# Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema

> **NCT02670720** · PHASE3 · TERMINATED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 6 (actual)

## Conditions studied

- Hereditary Angioedema
- HAE

## Interventions

- **DRUG:** avoralstat

## Key facts

- **NCT ID:** NCT02670720
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** preceding efficacy study of avoralstat in its current formulation was not significant and does not support continued development
- **Last updated:** 2016-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670720, "Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02670720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*